

# Supplementary Materials: The Natural Fungal Metabolite Beauvericin Exerts Anticancer Activity In Vivo: A Pre-Clinical Pilot Study

Daniela Heilos, Yelko Rodríguez-Carrasco, Bernhard Englinger, Gerald Timelthaler, Sushilla van Schoonhoven, Michael Sulyok, Simon Boecker, Roderich D. Süssmuth, Petra Heffeter, Rosa Lemmens-Gruber, Rita Dornetshuber-Fleiss and Walter Berger

## 1. Supplementary Materials and Methods

### 1.1 Cell Cycle Analysis

KB-3-1 cells ( $3.5 \times 10^5$ /per well) were seeded into 6-well plates and treated the next day with the indicated concentrations of beauvericin. After incubation at 37°C for another 24 h, cells were trypsinized, centrifuged (8 min, 300g, RT) and fixed in 70% ethanol and stored at -20°C overnight. Fixed cells were centrifuged (1 min, 6000g) and resuspended in 100  $\mu$ L of 0.9% NaCl. RNA was digested with 0.2 mg/mL of RNase for 30 min at 37°C. DNA was stained with propidium iodide (PI, 0.01 mg/mL, Sigma-Aldrich St. Louis, Missouri, USA) for 30 min at 4°C in the dark. Afterwards, cells were analyzed by flow cytometry using FACS Calibur (BD Biosciences, Franklin Lakes, New Jersey, USA) as described previously [1]. CellQuest Pro software (BD Biosciences) was utilized to determine percentages of the respective cell cycle phases.


### 1.2 Annexin-V/PI Staining

KB-3-1 cells were seeded ( $2 \times 10^5$  cells/well) and treated on the following day for 24 h with the indicated concentrations of beauvericin. Cells were trypsinized, centrifuged (300g, 5 min) and resuspended in 100  $\mu$ L buffer A (10 mM HEPES, 140 mM NaCl and 2.5 mM  $\text{CaCl}_2$ ) and stained for 15 min in the dark with PI (1  $\mu$ g/mL) and Annexin-V-APC (20  $\mu$ L/mL, BD Biosciences). Two-hundred  $\mu$ L of buffer A were then added and 10,000 cells were measured by FACS analysis (FACSCalibur; Becton Dickinson). Percentages of viable, early and late apoptotic cells and of necrotic cells were determined by CellQuest Pro software (Becton, Dickinson and Company, NY, USA).


### 1.3 Western Blot Analysis

Total protein lysates of KB-3-1 cells after 24 h-treatment with beauvericin were prepared according to standard procedures, separated by SDS-PAGE, and transferred to a polyvinylidene difluoride membrane for Western blotting as described previously [1]. The following primary antibodies specific for the following targets were diluted 1:1000 in TBST/3% BSA (w/v): PARP, Bak, Bax, Bim, Bcl-xL (polyclonal, Cell Signaling Technology, Beverly, MA, USA), caspase 9, cl. caspase 9 (monoclonal, Cell Signaling Technology) and  $\beta$ -actin (monoclonal, Clone AC-15, Sigma-Aldrich). Secondary horseradish peroxidase-labeled antibodies (goat anti-rabbit or anti-mouse, Santa Cruz Biotechnology, Dallas, Texas, TX, USA) were diluted 1:10,000 in TBST/1% BSA.


## 2. Supplementary Figures




**Figure S1.** Cell viability of murine fibroblasts NIH-3T3 (black circles) and colon carcinoma CT-26 cells (open squares) after treatment for 72 h with the indicated concentrations of beauvericin (BEA) is shown. For each cell line, viability was compared to untreated cells. Mean relative values ( $\pm$  SD) of triplicate of one representative experiment out of three are shown. The  $\text{IC}_{50}$  level is indicated by the dashed line.



**Figure S2.** Cell viability of beauvericin-treated human malignant versus non-malignant cells. (a) Non-malignant human keratinocytes (HaCaT, black circles) and colon carcinoma cell lines SW480 (gray squares) and SW620 (open squares) as well as (b) cervix carcinoma cell lines KB-3-1 (open squares), ME-180 (black asterisk) and GH354 (gray triangle) were treated with the indicated concentrations of beauvericin for 72 h. For each cell line, viability was compared to untreated cells. Mean values ( $\pm$  SD) of triplicate of one representative experiment are given. The  $\text{IC}_{50}$  level is marked with a dashed line.



**Figure S3.** Impact of beauvericin (BEA) on cell viability of murine non-malignant fibroblasts NIH-3T3 (black circles), human non-malignant keratinocytes HaCaT (open circles), murine colon carcinoma CT-26 (asterisks), human cervix carcinoma KB-3-1 (gray triangle) and human colon carcinoma SW480 cells (gray square) at higher density. Cells were grown to a 50-60% confluence and treated with the indicated concentrations of beauvericin for 72 h. The IC<sub>50</sub> level is indicated by the dotted line. Mean values (± SD) of one representative experiment in triplicate are shown.



**Figure S4.** Effects of beauvericin treatment on KB-3-1 cells. (a) Percentages of cells in the G2/M (open bars), S (gray bars) or G0/G1 (black bars) phase of the cell cycle among viable cells (=100%) were determined by PI staining after treatment for 48 h with the indicated concentrations of beauvericin. (b) Mean percentages (± SD) of early (white bars) and late apoptotic (gray bars) and of necrotic cells (black bars) were determined by Annexin-V/PI staining after cells were treated for 24 h with the indicated concentrations of beauvericin. Significant differences to untreated controls are marked by asterisks (\*\*\*)p<0.001). (c) Expression of PARP and caspase 9 and amount of cleaved (Cl.) PARP and cleaved Caspase 9, as well as protein expression of Bim, Bax, Bak and Bcl-xL in beauvericin-treated (24 h) and untreated cells were determined by Western Blotting. β-actin served as loading control.

## 3. Supplementary Table

Table S1. Description of cell lines used in this study.

Cell line (ATCC Nr.)	Tissue (organism)	Medium	Source
3T3/NIH (CRL-1658)	fibroblasts (mouse)	DMEM + 10% FBS	ATCC
CT-26 (CRL-2638)	colon carcinoma-derived cell line (mouse)	DMEM/Ham's Nutrient Mixture F12 (Sigma Aldrich, St. Louis, USA) + 10% FBS	ATCC
GH354 (CRL-13003)	cervix adenocarcinoma- derived cell line (human)	RPMI 1640 + 10% FBS	ATCC
HaCaT	keratinocytes (human) [2]	DMEM + 10% FBS	Dr. N.E. Fusenig (Heidelberg, Germany)
KB-3-1	HeLa derivative, cervix carcinoma-derived cell line (human)	RPMI 1640 + 10% FBS	Dr. Shen (Bethesda, USA)
ME-180 (HTB-33)	cervix; derived from metastatic site: omentum (human)	RPMI 1640 + 10% FBS	ATCC
SW480 (CCL-228)	colorectal adenocarcinoma, Dukes type B-derived cell line (human)	MEME + 10% FBS	ATCC
SW620 (CCL-227)	colon; cell line derived from metastatic site: lymph node (human)	MEME + 10% FBS	ATCC

ATCC, American Type Culture Collection, Rockville, MD, USA; DMEM, Dulbecco's modified Eagle's medium; RPMI, Roswell Park Memorial Institute; MEME, Minimum Essential Medium Eagle medium; FBS, fetal bovine serum (Sigma-Aldrich, St. Louis, USA);

## References

1. Dornetshuber-Fleiss, R.; Heffeter, P.; Mohr, T.; Hazemi, P.; Kryeziu, K.; Seger, C.; Berger, W.; Lemmens-Gruber, R. Destruixins: Fungal-derived cyclohexadepsipeptides with multifaceted anticancer and antiangiogenic activities. *Biochem. Pharmacol.* **2013**, *86*, 361–377.
2. Boukamp, P.; Petrussevska, R.T.; Breitkreutz, D.; Hornung, J.; Markham, A.; Fusenig, N.E. Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line. *J. Cell Biol.* **1988**, *106*, 761-771.